New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

April 05, 2021
A phase II trial of a novel, lesion-directed antithrombotic agent shows no effect on preventing myocardial injury in low-risk patients undergoing PCI, but the safety profile was good with few bleeding events. Trialists believe the disappointing results don’t rule out a role for the agent in higher-risk settings.
Revacept (advanceCOR), an intravenous, competitive antagonist to platelet glycoprotein VI (GPVI), efficiently binds to collagen and effectively mimics the GPVI pathway, blocking platelet aggregation. The appeal of the agent stems from prior studies suggesting that it would permit
fast and powerful platelet inhibition at the site of the atherosclerotic plaque injury, without increasing the risk of bleeding more systemically. Past research has shown limited success with a similar agent derived from snake venom.

Related Keywords

Germany , Munich , Bayern , German , Deutsches Herzzentrum , Katharina Mayer , Steffen Massberg , Md Ludwig Maximilian University Of Munich , Ludwig Maximilian University , ஜெர்மனி , முனிச் , பேயர்ன் , ஜெர்மன் , காதரின மேயர் , ம்ட் லுட்விக் மாக்ஸிமிலியன் பல்கலைக்கழகம் ஆஃப் முனிச் , லுட்விக் மாக்ஸிமிலியன் பல்கலைக்கழகம் ,